Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bayer to Sell Diagnostics Division to Siemens for $5.3 Billion

By HospiMedica staff writers
Posted on 07 Jul 2006
Following on the heels of its successful takeover of drug company Schering AG (Berlin, Germany), the Bayer Group (Leverkusen, Germany) has taken a move that will enable still more concentration on pharmaceuticals by announcing plans to sell its diagnostics division to Siemens AG (Munich, Germany) for about U.S.$5.3 billion.

"We are concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients,” explained Werner Wenning, chairman of the management board at Bayer AG.

The Diabetes Care Division will not be included in the sale nor will the diagnostic imaging business of Schering AG. More...
However, the systems business of the Diagnostics Division, with its emphasis on hardware, information technology (IT) networking, and laboratory equipment, is subject to different success factors, according to Bayer, and therefore will be included in the sale.

"Bayer Healthcare Diagnostics has grown considerably faster than the market in terms of earnings and profitability over the past three years,” said Arthur Higgins, chairman of the board of management of Bayer HealthCare AG. "So now is the right time to divest this successful business and thereby add value for the Bayer Group. Siemens is the ideal company to continue developing Bayer HealthCare Diagnostics as a core business.”

"With this acquisition we are continuing to consistently pursue our strategy of building the industry's first integrated diagnostics company that combines diagnostic imaging, laboratory diagnostics, and clinical information technology under one roof right along the value chain,” observed Erich Reinhardt, CEO and president of Siemens Medical Solutions.

The transaction will also help Bayer to reduce some of the debt incurred for the financing and acquisition of Schering.



Related Links:
Siemens AG
Bayer AG

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.